[Hungarian Philadelphia negative chronic myeloproliferative neoplasia registry. Evaluation of the Polycythemia vera patients]

Orv Hetil. 2017 Jun;158(23):901-909. doi: 10.1556/650.2017.30766.
[Article in Hungarian]

Abstract

Intruduction and aim: The Hungarian National Registry for Philadelphia chromosome negative myeloproliferative neoplasms has been developed. The aim of the recent study is to assess the clinical characteristics of Hungarian patients with polycythemia vera.

Method: Data of 351 JAK2V617F and exon 12 mutation positive polycythemia vera patients were collected online from 15 haematology centres reporting epidemiologic, clinical characteristics, diagnostic tools, therapeutic interventions, thromboembolic complications, disease transformations. Vascular events prior to and after diagnosis were evaluated upon the Landolfi risk assessment scale.

Results: 116 thromboembolic events were reported in 106 PV patients prior to diagnosis and 152 occasions in 102 patients during follow-up. The frequency of major arterial events were significantly reduced (p<0.0001) and the minor venous events were significantly elevated (p<0.0001) after the diagnosis. Major hemorrhagic complications were found in 25 and transformation in 26 cases.

Conclusions: Our registry allows to collect and evaluate the features of patients with polycythemia vera. The Landolfi risk stratification was proven to be useful. Based on evaluated data, accuracy of diagnostic criteria and compliance to risk-adapted therapeutic guidelines are needed. Orv Hetil. 2017; 158(23): 901-909.

Keywords: Landolfi risk stratification; Landolfi-rizikóbecslés; cardiovascular risk factors; cardiovascularis rizikófaktor; myeloproliferativ neoplasia; myeloproliferative neoplasms; polycythaemia vera; polycythemia vera; registry; regiszter.

MeSH terms

  • Age Distribution
  • Aged
  • Female
  • Humans
  • Hungary
  • Male
  • Middle Aged
  • Philadelphia Chromosome
  • Polycythemia Vera / epidemiology*
  • Primary Myelofibrosis / epidemiology*
  • Registries*
  • Risk Assessment
  • Risk Factors
  • Sex Distribution